Edition:
United Kingdom

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

313.45DKK
16 Feb 2018
Change (% chg)

kr.8.25 (+2.70%)
Prev Close
kr.305.20
Open
kr.309.50
Day's High
kr.314.65
Day's Low
kr.306.85
Volume
3,014,036
Avg. Vol
3,083,445
52-wk High
kr.354.80
52-wk Low
kr.230.20

Select another date:

Fri, Feb 9 2018

BRIEF-Novo Nordisk Says Diabetes Drug Ozempic Has Been Approved In The EU

* OZEMPIC (SEMAGLUTIDE) APPROVED IN EU FOR TREATMENT OF TYPE 2 DIABETES​

BRIEF-Novo Nordisk Launches Rebinyn In The United States For People With Hemophilia B

* NOVO NORDISK LAUNCHES REBINYN® IN THE UNITED STATES FOR PEOPLE WITH HEMOPHILIA B Source text for Eikon: Further company coverage:

In diabetes war, Novo Nordisk aims to break mold with new pill

LONDON After nearly a century building a company worth $125 billion based on injectable drugs, Denmark's Novo Nordisk - the world's biggest insulin maker - wants to prove this year it can transform the diabetes market with a pill.

FOCUS-In diabetes war, Novo Nordisk aims to break mould with new pill

LONDON, Feb 6 After nearly a century building a company worth $125 billion based on injectable drugs, Denmark's Novo Nordisk - the world's biggest insulin maker - wants to prove this year it can transform the diabetes market with a pill.

BRIEF-Novo Nordisk Launches Ozempic And Fiasp In The U.S.

* BOTH DIABETES MEDICATIONS RECEIVED APPROVAL FROM THE U.S. FOOD AND DRUG ADMINISTRATION IN 2017 Further company coverage: (Copenhagen newsroom)

BRIEF-Novo Nordisk Announces Availability Of New Diabetes Medications At Pharmacies Across U.S.

* NOVO NORDISK - ANNOUNCED AVAILABILITY OF NEW DIABETES MEDICATIONS, OZEMPIC INJECTION 0.5 MG OR 1 MG AND FIASP 100 UNITS/ML AT PHARMACIES ACROSS U.S. Source text for Eikon: Further company coverage:

BRIEF-NNIT: ‍Novo Nordisk And Novo Holdings Swap Holding In Company

* ‍NOVO HOLDINGS A/S ("NOVO HOLDINGS") HAS INCREASED ITS SHAREHOLDING IN NNIT​

Novo Nordisk CEO welcomes Amazon, Berkshire, JPMorgan pharma company

COPENHAGEN, Feb 1 Novo Nordisk's chief executive welcomes that Amazon.com Inc, Berkshire Hathaway Inc and JPMorgan Chase & Co, has established a new company to cut health costs for their employees.

BRIEF-Novo Nordisk To Initiate Cardiovascular Outcomes Study With Diabetes Drug Ozempic in 2018

Feb 1 NOVO NORDISK'S CHIEF SCIENTIFIC OFFICER MADS KROGSGAARD THOMSEN SAYS:

BRIEF-Novo Nordisk CEO: We Remain Committed To Grow In Biopharma Segment, Also Via Acquisitions

* NOVO NORDISK CEO SAYS WE REMAIN COMMITTED TO GROWTH IN THE BIOPHARMA SEGMENT, ALSO VIA ACQUISITIONS Further company coverage: (Reporting by Jacob Grønholt-Pedersen)

Select another date: